Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Daniel K. Kajdasz"'
Autor:
Michael, Liebowitz, Harry A, Croft, Daniel K, Kajdasz, Heidi, Whalen, Susan, Gallipoli, Maria, Athanasiou, Carol R, Reed
Publikováno v:
Psychopharmacology bulletin. 44(3)
Vilazodone is a selective serotonin reuptake inhibitor and 5-HTPooled data from two 8-week, double-blind studies of vilazodone (n = 436) vs placebo (n = 433) and data from one 52-week, open-label study (n = 616, vilazodone only) were analyzed. Patien
Autor:
Susan Gallipoli, Heidi Whalen, Michael E. Thase, Carol R. Reed, Maria Athanasiou, Daniel K. Kajdasz
Publikováno v:
Current Medical Research and Opinion. 28:27-39
Vilazodone is a novel serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder (MDD). This evaluation presents side-by-side efficacy data from two randomized, double-blind, placebo
Autor:
Art Wamil, Susan Gallipoli, Donald S. Robinson, Carol R. Reed, Heidi Whalen, Daniel K. Kajdasz
Publikováno v:
Journal of Clinical Psychopharmacology. 31:643-646
Vilazodone, a selective serotonin (5-HT) reuptake inhibitor and 5-HT(1A) receptor partial agonist, was efficacious in two 8-week placebo-controlled studies in adults with major depressive disorder. This open-label, multicenter study assessed the long
Autor:
Arif Ullah Khan, Carol R. Reed, Daniel K. Kajdasz, Susan Gallipoli, Donald S. Robinson, Andrew J. Cutler, Heidi Whalen, Maria Athanasiou
Publikováno v:
The Journal of Clinical Psychiatry. 72:441-447
Objective To evaluate the efficacy, and further establish the safety profile, of oral once-daily vilazodone, a potent and selective serotonin 1A receptor partial agonist and reuptake inhibitor, in the treatment of major depressive disorder (MDD). Met
Autor:
James I. Hudson, Amy S. Chappell, Fujun Wang, Lesley M. Arnold, Madelaine M. Wohlreich, Daniel K. Kajdasz, Apurva Prakash
Publikováno v:
The Clinical Journal of Pain. 25:461-468
To investigate whether comorbid major depressive disorder (MDD) influenced the efficacy and safety of duloxetine in treating fibromyalgia (FM).This was a post-hoc analysis using pooled data from 4 double-blind, placebo-controlled studies of patients
Autor:
Deborah N. D'Souza, Morton Scheinberg, Harvey Moldofsky, Daniel K. Kajdasz, Amy S. Chappell, Geoffrey O. Littlejohn
Publikováno v:
The Clinical Journal of Pain. 25:365-375
Evaluate the efficacy and safety of duloxetine at doses up to 120 mg once daily in patients with fibromyalgia.This was a phase 3, 60-week study, which included an 8-week open-label period followed by a 52-week, randomized, double-blind period. Patien
Publikováno v:
International Clinical Psychopharmacology. 23:317-324
The objective of this study was to conduct a meta-analysis of the clinical impact of duloxetine treatment on sleep in adults with major depressive disorder. Data were pooled from 11 placebo-controlled, double-blind studies of duloxetine treatment (8-
Publikováno v:
Current Medical Research and Opinion. 24:3105-3115
Debate continues regarding whether onset of analgesia is faster than antidepressant effect in antidepressants with both properties. Duloxetine hydrochloride (from here on referred to as duloxetine) is effective in both major depressive disorder and d
Autor:
I. Jon Russell, Amy S. Chappell, Madelaine M. Wohlreich, Daniel J. Walker, Philip J. Mease, Timothy R. Smith, Lesley M. Arnold, Michael J. Detke, Daniel K. Kajdasz
Publikováno v:
Pain. 136:432-444
The primary objectives of this study were to assess the efficacy and safety of duloxetine for reducing pain severity in fibromyalgia patients with or without current major depressive disorder. This was a 6-month, multicenter, randomized, double-blind
Autor:
Rakesh K. Jain, James M. Russell, Michael E. Thase, Debbie M. Froud, Michael Bauer, Y. Pritchett, David G.S. Perahia, Kimberly A. Spencer, Joel Raskin, Daniel K. Kajdasz, Daniel J. Walker
Publikováno v:
Journal of Psychiatric Research. 42:22-34
Background Clinical trials assessing antidepressant therapies typically include separate assessments of efficacy (benefit) and adverse events (risk). Global benefit–risk (GBR) assessment allows the simultaneous evaluation of both efficacy and adver